BIT Share Price Performance
AU$0.002
-0.03 (-93.33%)
Price AU$0.002
Share PriceAU$0.002
BIT Community Narratives
There are no narratives available yet.
Recent BIT News & Updates
No updates
Biotron Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0011
- Gross Margin
- 100.00%
- Net Profit Margin
- -78.04%
- Debt/Equity Ratio
- 0%
Biotron Limited Competitors
About BIT
- Founded
- 1999
- Employees
- n/a
- CEO
- WebsiteView website
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.
Australian Market Performance
- 7 Days: -0.4%
- 3 Months: 6.8%
- 1 Year: 13.2%
- Year to Date: 5.2%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Meanwhile, the market is actually up 13% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading